Introduction
A number of viruses, such as Influenza A, poliovirus, cytomegalovirus, herpes simplex virus, human immnodeficiency virus 1 (HIV-1) and human rhinovirus type-9 (HRV-9) (Ahmad et al., 1987; Eggers and Rosenwirth, 1988 ; reviewed by Field and Goldthorpe 1989) , have been shown to develop resistance to antivirals.
Chalcone Ro 09-0410 (4'-ethoxy-2' -hydroxy-4.6'dimethoxy chalcone) is active against most human rhinoviruses at minimal inhibitory concentrations (MIG) ranging from 0.003 to 3.0 J.Lg mr'. The drug is thought to interact directly with the viral capsid protein and thus inhibits virus uncoating (Ishitsuka et al., 1982a,b; Ninomiya et al., 1984) .
As part of a programme to study the mechanisms by Which drug resistance evolves and the pathogenic potential of resistant mutants for man, we isolated a number of HRV-2 drug-resistant and -dependent mutants. In this study, we describe the isolation and characterization of an HRV-2 mutant which is resistant to Ro 09-0410 in Ohio HeLa cells. Table 1 shows the titres of virus following passage at different concentrations of Ro 09-0410. The data clearly show that a drug-resistant mutant had been selected which was able to grow equally well in both the presence and absence of Ro 09-0410. Thus the virus from passage number IX had a titre of 10 5 . 8 and 10 6 ,8 TCID 50 mr' in the presence and absence of drug, respectively. The MIC of Ro 09"0410 required to inhibit the drug-resistant mutant was 8.192 J.Lg mr", compared to 0.032 J.Lg rnr' for the wild-type virus.
Results

Preparation of the drug-resistant SR2-041 0 viruses
Pleque formation by SR2-0410 virus SR2-0410 produced no plaques under a standard 0.2% agarose overlay, while the parental wild-type HRV-2 produced large, clear, round plaques.
Single-cycle growth curve of SR2-041O virus
There were no significant differences between the growth pattern of the SR2-0410 virus and that of the parental wild-type HRV-2 during a 1D-12h cycle in the absence of Ro 09-0410 (data not shown). Similarly, as demonstrated in Table 4 , monoclonal antibody 805 failed to efficiently neutralize the drug-resistant virus SR2-0410 compared with the Wild-type (P = 0.0142). Thus the drug-resistant virus required some four-fold increase in monoclonal antibody concentration to reach the same neutralization end-point as that required by the wild-type. Table 5 shows that the SR-0410 virus was also resistant to other antiviral agents, such as BW 683C77, WIN 51711 and R 61 837, but not to enviroxime. Similarly, Table 6 shows that the SR2-0410 virus was resistant to various combinations of Ro 09-0410 with other synthetic antirhinovirals, except for those with enviroxime.
Cross-resistance to other synthetic anti-rhinovirus compounds
compared to the wild-type HRV-2 (data not shown). Thus, at higher temperatures (35°C and 37°G), CPE was observed within 48 h of infection whereas, at these temperatures, the parental wild-type virus did not produce CPE until 72 h after infection. Furthermore, during the first 4 days of observations the CPE produced by the SR2-0410 virus was much more extensive than that produced by the parental virus.
Genetic stability of SR2-041O virus
Six of the SR2-0410 viruses (Nos V, VI, VII, VIII, IX and X), generated in vitro by serial selection in increasing concentrations of Ro 09-0410, were passaged three times in the absence of their respective concentration of Ro 09-0410 and the virus at each passage level was tested for sensitivity to the drug ( Table 7 ).The results show that there was a gradual loss of resistance to Ro 09-0410 on further passage in the absence of the drug. Ninomiya et al. (1984) showed that Ro 09-0410 interacts with the capsid protein of HRV-2 and protects the virus against inactivation when exposed to low acid pH and high temperature. They also showed that a subtype of HRV-2 resistant to Ro 09-0410 (NR2-1) did not interact with the wt HRV-2
Neutralization of SR2-041 0 with specific anti-HRV-2 polycolonal and monoclonal antibodies
The SR2-0410 virus required at least a four-fold higher concentration of anti-HRV-2 serum to be neutralized compared with the parental wild-type HRV2 (10-2 . 9 or 1 :800 dilution versus 10-3 . 5 or 1 :3200 dilution, respectively; P = 0.0417; Table 3 ). Table 2 shows that exposure of SR2-041 0 to pH 5 in the presence of drug provided only partial protection against low pH. Thus, virus titre was reduced approximately 1000-fold when exposed to pH 5 in the presence of Ro 09-0410 (10 4 . 5 versus 10 7 . 5 TClD 50 mr ' at pH 5 and pH 7, respectively). In contrast, the titre of the parental wild-type HRV-2 was reduced by only 10-fold (10 6 . 2 versus 10 7 . 5 TCID 50 rnr" at pH 5 and pH 7, respectively). Furthermore, SR2-0410 was almost totally inactivated at 56°C in the absence (titre 10°. 2 TCID 50 mr') and presence (10°. 8 TCID 50 mr') of Ro 09-0410. In contrast, the parental wild-type HRV-2 was substantially protected when exposed to such a temperature in the presence of the drug (titre 10 4 . 5 TCID 50 rnr') compared with the absence of the drug (10°. 8 TCID 50 rnt"), wild-type virus. This suggests that acquiring resistance to Ro 09-0410 also affected the antigenic determinants recognized by the neutralizing antibodies. Indeed, one of the monoclonal antibodies used in this study, 805, failed to efficiently neutralize the drug-resistant mutant compared with the wild-type when both were tested under the same test conditions. A mutation in VP1 at position 276 results in a change from Thr to either lie or Ala, allowing the wild-type HRV-2 to escape neutralization by monoclonal antibody 805 (W. Barclay, personal communication). Therefore, our results suggest that acquiring drug resistance may result in some change in the amino acid sequence present in that region of the antigenic site. This is in contrast to previous findings that a subline of HRV-2 resistantto Ro 09-041 0, NR2-1 (Ninomiya etal., 1985) and an arildone-resistant Poliovirus type-2 (Eggers and Rosenwirth, 1988) were neutralized by their respective antisera as well as the parental virus. This difference also needs a molecular explanation, since the drug is inserted into the canyon region while the antigenic epitopes are in the areas on the virus surface surrounding the canyon (Smith et al., 1986) .
Acid and heat stability of SR2-0410 virus
Our studies show that resistance to Ro 09-0410 is relatively stable, although there was evidence of some gradual loss of drug resistance after three passages in the absence of the drug. Eggers and Rosenwirth (1988) , on the other hand, showed that arildone-resistant mutants were very stable after passage in the absence of the drug. However, they measured genetic stability in terms of virus titres of the resistant mutants after five passages in the absence of the drug. In this study we have estimated both the titre of the virus (data not presented) and the drug sensitivity of the mutant after each passage in the absence of the drug and shown that although the virus titres were not generally affected there was, however, a gradual increase in sensitivity to Ro 09-0410 after each passage without the drug. Nevertheless, acquiring resistance to Ro 09-0410 also resulted in cross-resistance to other syntheticcompounds, such as BW683C77, WIN51711 and R 61 837, all of which, like Ro 09-0410, are thought to interact directly with the viral capsid protein and probably inhibit uncoating (Tisdale and Selway, 1983; Ninomiya et al., 1985; Ishitsuka et al., 1986; Fox et al., 1986; Smith et al., 1986; AI-Nakib and Tyrrell, 1987; Andries et al., 1988) . SR2-0410 virus, however, as expected, was sensitive to agent and was inactivated when exposed to pH 5.0. Our drug-resistant mutant, SR2-0410, has shown a similar pattern when exposed to low pH (5.0) and high temperature (56°C). Therefore, it appears that a change in the viral capsid protein, as a result of acquiring resistance to Ro 09-0410, is also associated with a loss in the ability of the drug to bind to the virus. As a result of this, the drug is unable to interact with the viral capsid and protect the virus against inactivation when exposed to low pH and high temperature. Acquiring resistance to Ro 09-041 0 also altered or reduced the ability of the virus to plaque normally, as has been seen with Ro 09-0410-resistant HRV-9 (Ahmad et al., 1987) and mutants of HRV-14 (Colonno et al., 1988) . Nevertheless, our SR2-0410 virus showed a single-cycle growth curve that was similar to that of the parental wild-type HRV-2, which suggests that acquiring drug resistance does not necessarily affect the ability of the virus to grow in cell cultures, such as Ohio HeLa cells. Indeed, Colonno et al. (1988) showed that amino acid substitutions were affecting additional viral processes distinct from attachment and replication. Eggers and Rosenwirth (1988) also showed that an arildone-resistant Poliovirus type-2 was able to infect and grow in cell culture in a manner similar to that of the parental virus. We also investigated whether drug resistance affected virus growth at higher temperatures, such as 35°C and 37°C and, found that SR2-0410 was better adapted than the parental wild-type virus to grow at high temperatures. This is in contrast to previous work on the temperature sensitivity of Ro 09-0410-resistant HRV-9 mutants (Ahmad et et., 1987) , which showed that such viruses, like the parental HRV-9 strain, grew better at 33°C. If this is confirmed, it will be of interest to discover why mutants that confer drug resistance have had different effects in these two cases. Our SR2-041 O-drug resistant virus was not as efficiently neutralized by our anti-HRV-2 serum as the parental 
Selection of the drug-resistant mutant SR2-041 0
Cytotoxicity and estimation of MIC Table 6 . Synergy between anti-rhinovirus compounds againstwl HRV-2 and SR2-0410 (100 TCI050 mr ') expressed as FIC' index.
Rhinovirus-sensitive Ohio HeLa cell monolayers were infected with 0.2ml of HRV-2 parental strain (10 8 . 5 TCID 501ml) in the FICindex wl HRV-2 SR2-0410 Chalcone Ro 09-0410 Compound These were conducted as described previously (AI-Nakib and Tyrrell, 1987) . enviroxime, which has a different mode of action and is thought to interfere with rhinovirus viral RNA synthesis (AI-Nakib and Tyrrell, 1987) .
It was particularly interesting to show in this study that because of cross-resistance, combination therapy is unlikely to be useful unless the antivirals in the combination are carefully selected. Thus, they must show not only synergistic activity but must also have different modes of action if they are to be effective in the treatment of resistant viruses.
Clearly we must now look for molecular changes in our SR2-0410 virus in order to understand how these have altered the biological properties of the parental wild-type virus. Indeed, we are at present sequencing the genome of our resistant virus and comparing it with that of the parental strain. The wild-type HRV-2 strain was obtained from the nasal wash of a volunteer at the Common Cold Unit, Salisbury. The virus was passaged twice in Ohio HeLa cells and a pool of this virus was prepared and titrated.
Materials and Experimental procedures
Rhinovirus-sensitive Ohio HeLa cells were cultured at 37"C in Eagle's basal medium (BME) containing 10% newborn calf serum, 0.088% sodium bicarbonate and 50 flog rnr" of gentamicin. Maintenance medium consisted of BME, 2% fetal calf serum (FCS), 50 flog rnr' of gentamicin, 5% tryptose phosphate broth, 30mM magnesium chloride, 2.5 flog ml-1fungizone, 1 mg rnr' neomycin, pencillin-G 50u mr" fungizone, 1 mg rnr ' and streptomycin sulphate 100 flog mr".
Ohio HeLa cell overlay consisted of 10% minimum essential medium (MEM), 4.4% sodium bicarbonate, 2% FCS, 2% of 3M magnesium chloride, 2% DEAE-Dextran, 0.2% agarose (Indubiose A37, BF; IBF Biotechnics, France), distilled water and antibiotics.
The methods used for growing and determining the infectivity of HRV-2 in tissue culture have been described in more detail recently (AI-Nakib and Tyrrell, 1988) .
Anti-rhinovirei compounds
The chalcone Ro 09-0410 (4' -ethoxy-2'-hydroxy-4,6' -dimethoxy chalcone) was kindly supplied by Dr I. Lennox An FICindex of <0.5 was takento indicatesignificantsynergism; 0.5--0.9 suggestive of synergism; 1.0 effects are additive; 1.1-1.9 indifference or partialantagonism and >2.0 indicatingantagonism. 
Plaque assay
Semi-confluent monolayers 'of Ohio HeLa cell grown in Petridishes (diameter 5 cm) were inoculated with 0.1 ml containing 100 TCID so of either the parental wild-type HRV-2 or SR2-041O. After 90 min of adsorption at room temperature, the cells were overlaid and incubated in an atmosphere of 5% CO 2 for 48h. The cells were then stained with 0.01% neutral red for 24h and examined for plaques.
absence and presence of Ro 09-041 0 starting with a subinhibitory concentration ofO.016fL9 ml-1 (Fig. 1) .When 75-90% of the cells showed CPE, the cultures were frozen and thawed three times, and 0.2 ml was used to infect new Ohio HeLa cell monolayers maintained in medium with an increased concentration of drug (Table 1 ). The starting virus was considered as passage I. Virus from passage IX was cloned three times by limiting dilution in the presence of 0.512fL9 ml " of Ro 09-0410 to a more homogeneous preparation of SR2-0410; the highest dilution of the cloned virus that produced CPE in cell culture was harvested in the presence of Ro 09-0410 (0.512 fL9 mr').
Drug resistance in this study was defined as the ability of a virus mutant to produce a CPE equally well in the presence and absence of an anti-rhinoviral compound at a concentration that completely inhibited the CPE of the parental wild-type virus.
Statistical analysis
Data were analysed by a statistical package (Microstat) on a PC computer.
Neutralization tests using polyclonal antisera
These were carried out as recently described (AI-Nakib and Tyrrell, 1988) .
Cross-resistance to individual and combinations of anti-rhinoviral compounds
The combined effect of Ro 09-041 0 with other antiviral agents against HRV-2 and the drug-resistant virus SR2-0410, and studies on cross-resistance of SR2-0410 to other antivlrals, were conducted as described previously (Ahmad et al., 1987; AI-Nakib and Tyrrell, 1987) .
Neutralization tests using monoclonal antibodies
Serial doubling dilutions of mouse monoclonal antibodies (Ab 805, 811 and 819, with neutralizing tltres, determined by the plaque assay, of 1: 2500, 1: 3000, 1: 1000, respectively) were made in Ohio HeLa maintenance medium and incubated with an equal volume of 100 TCID so mr' of HRV-2 or SR2-0410 virus for 1 h at room temperature using a 96-well culture plate. Ohio HeLa cells (3 x 10 s cells rnr' in 100fLi of BME medium) were added, and plates were incubated at 33°C for 5 days under 5% CO 2 . The neutralizing monoclonal antibody titre was taken as the highest dilution that gave complete protection against challenge with 100 TCIDso rnr' of virus. mAb 805 and mAb 811 react with epitopes present on an antigenic site equivalent to site 2 (Nlm II)on HRV-14 (Rossmann et al., 1985) , whereas mAb 819 reacts with an epitope present on an antigenic site equivalent to site 1 (Nlm 1a) on HRV-14 (Rossmann et al., 1985) . The monoclonal antibodies were kindly supplied by Dr M. Francis of the Wellcome Biotechnology Group, Beckenham, Kent, UK.
Acid and heat stability tests in the presence and absence of the drug and extraction of the drug with chloroform were conducted as previously described (Ninomiya et al., 1984) .
Effect of temperature on OPE produced by SR2-0410
Ohio HeLa cell monolayers in 25 ern"plastic bottles were infected with 100 TCID so of either the parental HRV-2 or SR2-041O.Virus was allowed to adsorb with shaking for 90 min at room temperature. Bottles were fed with maintenance medium and incubated at either 33°C, 35°C or 3rc. CPE was monitored microscopically.
Acid and heat treatment of virus
Growth-curve experiments were carried out at 3rC in a hot room, as described recently (Eggers and Rosenwirth, 1988) .
Single-cycle growth in the absence of the Chalcone Ro 09-0410 The data presented in this paper represent results obtained in experiments that were shown to be reproducible on at least two occasions, and each result represents the average of three replicates.
